Volume 66, Issue 2, Pages (August 2004)

Slides:

Advertisements

Similar presentations

Kamyar Kalantar-Zadeh Kidney International

Advertisements

Volume 62, Issue 2, Pages (August 2002)

Volume 54, Issue 2, Pages (August 1998)

Volume 61, Issue 1, Pages (January 2002)

Changes in health-related quality of life after ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins Katy A.L. Darvall,

Changes in health-related quality of life after ultrasound-guided foam sclerotherapy for great and small saphenous varicose veins Katy A.L. Darvall,

Anemia management in chronic kidney disease

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Volume 90, Issue 5, Pages (November 2016)

Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Demetrios J. Kutsogiannis, R.T.Noel.

Kostas C. Siamopoulos, MD, FRSH, Chariklia Gouva, MD, Konstantinos P

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Robert W. Schrier, Raymond.

Volume 60, Issue 2, Pages (August 2001)

Volume 57, Issue 5, Pages (May 2000)

Volume 54, Issue 2, Pages (August 1998)

Volume 80, Issue 4, Pages (August 2011)

Kamyar Kalantar-Zadeh Kidney International

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Volume 63, Issue 4, Pages (April 2003)

Volume 66, Issue 3, Pages (September 2004)

Volume 61, Issue 6, Pages (June 2002)

Renal risk scores: Progress and prospects

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

The Effect of Resistance Exercise to Augment Long-term Benefits of Intradialytic Oral Nutritional Supplementation in Chronic Hemodialysis Patients Jie.

Volume 87, Issue 2, Pages (February 2015)

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

Volume 71, Issue 4, Pages (February 2007)

Prospective randomized study of individual and group psychotherapy versus controls in recipients of renal transplants1 Lyndsay S. Baines, John T. Joseph,

Volume 65, Issue 2, Pages (February 2004)

Volume 67, Pages S48-S51 (January 2005)

Elke Wühl, Otto Mehls, Franz Schaefer Kidney International

Locking of tunneled hemodialysis catheters with gentamicin and heparin

Volume 60, Issue 4, Pages (October 2001)

Volume 62, Issue 1, Pages (July 2002)

Fabia M.O. Pinho, Dirce M.T. Zanetta, Emmanuel A. Burdmann

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 64, Issue 1, Pages (July 2003)

Linda F. Fried, Trevor J. Orchard, Bertram L. Kasiske

Volume 56, Issue 2, Pages (August 1999)

Volume 76, Issue 8, Pages (October 2009)

Impact of thyroid dysfunction on serum cystatin C

Volume 66, Issue 4, Pages (October 2004)

Volume 80, Issue 3, Pages (August 2011)

Volume 66, Issue 3, Pages (September 2004)

Volume 76, Issue 12, Pages (December 2009)

Volume 63, Issue 2, Pages (February 2003)

Volume 57, Issue 1, Pages (January 2000)

Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors Barry M. Brenner, Joann Zagrobelny

Volume 60, Issue 3, Pages (September 2001)

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant Chirag R. Parikh, Peter Mcsweeney,

Volume 62, Issue 2, Pages (August 2002)

The Danish Renal Biopsy Register

Volume 80, Issue 10, Pages (November 2011)

Treatment of the primary hyperoxalurias: A new chapter

Volume 74, Issue 7, Pages (October 2008)

Volume 64, Issue 4, Pages (October 2003)

Volume 68, Issue 2, Pages (August 2005)

Volume 62, Issue 6, Pages (December 2002)

Volume 55, Issue 2, Pages (February 1999)

Volume 64, Issue 4, Pages (October 2003)

Volume 82, Issue 9, Pages (November 2012)

Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysis Nauman Siddiqi, Maureen A. McBride,

Volume 67, Issue 4, Pages (April 2005)

Volume 57, Pages S44-S48 (April 2000)

Bárbara Oriol, M. D. , Ana Barrio, M. D. , Alberto Pacheco, Ph. D

A. Lauschke, U.K.M. Teichgräber, U. Frei, K.-U. Eckardt

Rituximab treatment of idiopathic membranous nephropathy

Boxplots of diffusion (A and B) and perfusion (C) characteristics in brain metastases (gray), glioblastomas (white), and PCLs (dotted). Boxplots of diffusion.

Presentation transcript:

Volume 66, Issue 2, Pages 753-760 (August 2004) Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial Chariclia Gouva, Petros Nikolopoulos, John P.A. Ioannidis, Kostas C. Siamopoulos Kidney International Volume 66, Issue 2, Pages 753-760 (August 2004) DOI: 10.1111/j.1523-1755.2004.00797.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Hemoglobin levels at baseline and during follow-up (at 2, 4, 6, 9, and 12 months) in the deferred (white boxes) and early (gray boxes) treatment groups. The box plots show the median (horizontal line), interquartile range (box), and range (whiskers), unless there are also outliers and/or extreme values with 1.5 to 3 and >3 box lengths, respectively, away from the edge of the box, in which case these are shown by circles and asterisks. Kidney International 2004 66, 753-760DOI: (10.1111/j.1523-1755.2004.00797.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Serum creatinine levels at baseline and during follow-up (at 2, 4, 6, 9, and 12 months) in the deferred (white boxes) and early (gray boxes) treatment groups. The box plots show the median (horizontal line), interquartile range (box), and range (whiskers), unless there are also outliers and/or extreme values with 1.5 to 3 and >3 box lengths, respectively, away from the edge of the box, in which case these are shown by circles and asterisks. Not shown are two creatinine values above 10 mg/dL. Kidney International 2004 66, 753-760DOI: (10.1111/j.1523-1755.2004.00797.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Kaplan-Meier plots for doubling of creatinine, renal replacement, or death (A), and renal replacement or death (B) in the early (thick line) versus deferred (thin line) treatment arms. Kidney International 2004 66, 753-760DOI: (10.1111/j.1523-1755.2004.00797.x) Copyright © 2004 International Society of Nephrology Terms and Conditions